Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VT301 in mild-to-moderate Alzheimer's Disease
NCT05016427Phase 1Unknown
- Sponsor
- VTR Biotech
- Start
- Nov 2020
- Primary completion
- Nov 2021
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of VT301 in Alzheimer's disease (AD) (2 arms), sponsored by VTR Biotech. Primary endpoints: All Adverse Events (AE) at 3 months, Number of subjects with abnormal clinical Physical examination at 3 months and 4 more. Status: unknown.
02
Drugs
VT301
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05016427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05016427.